MALVERN, PA — TELA Bio, Inc. (Nasdaq: TELA) said it will replace four of its seven directors following its June 9 annual meeting and reported preliminary first-quarter revenue above prior guidance, as the company reshapes its board and advances its commercial operations.
The company announced that Chairman Doug Evans, along with directors Kurt Azarbarzin, Vince Burgess and Federica O’Brien, will step down at the conclusion of the meeting, with four new directors joining immediately after.
Joseph Capper, chief executive officer of MiMedx Group Inc. and former CEO of BioTelemetry, is expected to become chairman upon election. Guy Nohra, co-founder of Alta Partners; Joseph Neels, an operating partner at EW Healthcare Partners and former chief operating officer of Guidant; and Paul Thomas, chief executive officer of Prominex and former CEO of LifeCell, have been appointed to board roles effective after the meeting.
The changes represent a majority turnover of the board and add experience in medical technology commercialization, venture investment and corporate operations, the company said.
William Plovanic and Betty Jo Rocchio will stand for re-election, and Chief Executive Officer Antony Koblish will remain on the board, providing continuity.
Separately, TELA Bio reported preliminary first-quarter 2026 revenue of approximately $19.0 million, exceeding prior guidance of about $18.5 million. The company said the results are subject to adjustment pending completion of its quarterly review and financial closing procedures.
Full financial results for the quarter are scheduled to be released after the market close on May 12.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.